NEW YORK, NEW YORK, UNITED STATES — February 17, 2026 OS Therapies has announced a major global regulatory update for its investigational immunotherapy OST-HER2 targeting recurrent, fully resected pulmonary metastatic osteosarcoma, signaling accelerating progress toward potential biologics approval. The company confirmed submission of key Biologics License Application (BLA) modules to the U.S. Food and Drug Administration, alongside parallel regulatory advancement in the United Kingdom and Europe. The update positions OST-HER2 as one of the most closely watched immunotherapy candidates addressing high-risk osteosarcoma recurrence.
Science Significance
OST-HER2 represents a novel Listeria-based cancer immunotherapy platform engineered to stimulate targeted immune activation against HER2-expressing tumor cells. By leveraging attenuated Listeria bacteria, the therapy is designed to trigger potent antigen-specific immune responses capable of eliminating residual micrometastatic disease following lung metastasis resection. Biomarker analyses from clinical studies have demonstrated immune pathway activation signatures correlating with improved clinical outcomes and long-term survival in responder populations. Ongoing translational research aims to validate biomarker expression as surrogate endpoints for therapeutic efficacy, further strengthening the scientific rationale behind this targeted immuno-oncology strategy.
Regulatory Significance
Regulatory momentum for OST-HER2 is advancing across multiple global agencies. The company has submitted Non-Clinical and Chemistry, Manufacturing & Controls (CMC) modules of its BLA to the U.S. FDA, with the Clinical module expected following a Type D regulatory meeting. Concurrently, conditional Marketing Authorisation Applications (MAAs) are planned for submission to both the U.K. Medicines and Healthcare products Regulatory Agency and the European Medicines Agency. The therapy has already received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation, enabling eligibility for accelerated review pathways and potential Priority Review Voucher incentives upon approval.
Business Significance
Advertisement
From a commercial perspective, OST-HER2 represents the lead value driver within OS Therapies’ oncology pipeline. Accelerated approval pathways could significantly shorten time to market while enabling earlier revenue generation. The company is also preparing confirmatory trial designs in collaboration with international osteosarcoma key opinion leaders, with initiation targeted for 2026. Additionally, monetization opportunities exist through the potential sale of a Priority Review Voucher, historically valued in the hundreds of millions of dollars. Together, regulatory acceleration and incentive programs position OST-HER2 as a strategically important asset within the rare oncology therapeutics market.
Patients’ Significance
Pulmonary metastatic osteosarcoma remains one of the most aggressive and treatment-resistant bone cancers, particularly in pediatric and young adult populations. Even after complete surgical resection, recurrence risk remains high and survival outcomes are poor. OST-HER2 is being developed specifically to prevent or delay recurrence following lung metastasis removal, addressing a critical unmet need where few therapeutic options exist. By activating tumor-targeted immune surveillance, the therapy may extend event-free survival and improve long-term remission rates for high-risk patients.
Policy Significance
Rare pediatric cancers have become a priority focus for regulatory agencies and public health policymakers. Incentive frameworks such as orphan drug programs, fast-track designations, and pediatric disease vouchers are designed to stimulate innovation in underfunded therapeutic areas. OST-HER2’s eligibility across multiple expedited pathways underscores its alignment with global policy goals aimed at accelerating development of treatments for rare, life-threatening malignancies. Cross-regional regulatory coordination also reflects increasing harmonization of oncology approval strategies.
The global regulatory advancement of OST-HER2 highlights the convergence of immunotherapy innovation, rare cancer prioritization, and accelerated biologics review pathways. With BLA modules under review, biomarker data forthcoming, and confirmatory trials in planning, OS Therapies is moving closer to potential commercialization of a first-in-class osteosarcoma immunotherapy. If approved, OST-HER2 could redefine post-resection treatment standards for metastatic osteosarcoma while reinforcing the expanding role of targeted immune-oncology platforms in rare cancer care.
Source: OS Therapies press release
